SVILE regimen, a combination of dexamethasone, vindesine, ifosfamide, pegaspargase, and etoposide, for treating relapsed/refractory extranodal natural killer/T-cell lymphoma, nasal type (vol 96 106422, 2020
第一作者机构：[1]Capital Med Univ, Beijing Tongren Hosp, Dept Hematol, 1 Dong Jiao Min Xiang St, Beijing 100730, Peoples R China
通讯作者：
推荐引用方式(GB/T 7714)：
Wei Liqiang,Cong Jia,Yang Lei,et al.SVILE regimen, a combination of dexamethasone, vindesine, ifosfamide, pegaspargase, and etoposide, for treating relapsed/refractory extranodal natural killer/T-cell lymphoma, nasal type (vol 96 106422, 2020[J].LEUKEMIA RESEARCH.2020,99:doi:10.1016/j.leukres.2020.106446.
APA：
Wei, Liqiang,Cong, Jia,Yang, Lei,Ye, Jin,Li, Xin...&Wang, Jingwen.(2020).SVILE regimen, a combination of dexamethasone, vindesine, ifosfamide, pegaspargase, and etoposide, for treating relapsed/refractory extranodal natural killer/T-cell lymphoma, nasal type (vol 96 106422, 2020.LEUKEMIA RESEARCH,99,
MLA：
Wei, Liqiang,et al."SVILE regimen, a combination of dexamethasone, vindesine, ifosfamide, pegaspargase, and etoposide, for treating relapsed/refractory extranodal natural killer/T-cell lymphoma, nasal type (vol 96 106422, 2020".LEUKEMIA RESEARCH 99.(2020)
